Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions
Central Retinal Vein Occlusion, Non-Ischemic
Interventions
DRUG

Hydroxycarbamid

20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).

Trial Locations (1)

75012

RECRUITING

CHNO des Quinze-Vingts, Paris

All Listed Sponsors
collaborator

Hopital Universitaire Robert-Debre

OTHER

collaborator

Institut National de la Transfusion Sanguine

OTHER

collaborator

Keyrus Biopharma

OTHER

collaborator

For Drug Consulting

OTHER

collaborator

Theravia

INDUSTRY

lead

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

OTHER